Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer.

Frank MO, Kaufman J, Tian S, Suárez-Fariñas M, Parveen S, Blachère NE, Morris MJ, Slovin S, Scher HI, Albert ML, Darnell RB.

PLoS One. 2010 Sep 1;5(9). pii: e12367. doi: 10.1371/journal.pone.0012367.


Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.

Perambakam S, Hallmeyer S, Reddy S, Mahmud N, Bressler L, DeChristopher P, Mahmud D, Nunez R, Sosman JA, Peace DJ.

Cancer Immunol Immunother. 2006 Sep;55(9):1033-42. Epub 2005 Nov 10.


Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.

Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, Veelken H.

Int J Cancer. 2006 Nov 15;119(10):2428-34.


Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S.

Cancer Immunol Immunother. 2006 Dec;55(12):1524-33. Epub 2006 Apr 13.


Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.

Meidenbauer N, Harris DT, Spitler LE, Whiteside TL.

Prostate. 2000 May 1;43(2):88-100.


Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.

Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J.

J Clin Invest. 2002 Feb;109(3):409-17.


Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA.

Barrou B, Benoît G, Ouldkaci M, Cussenot O, Salcedo M, Agrawal S, Massicard S, Bercovici N, Ericson ML, Thiounn N.

Cancer Immunol Immunother. 2004 May;53(5):453-60. Epub 2004 Feb 4.


Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.

Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G, Giesler JM, Jüttner E, Peters JH, Häring B, Leo R, Unger C, Azemar M.

Prostate. 2007 Apr 1;67(5):500-8.


Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.


Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.

Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF.

Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72.


Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.

Wieckowski E, Chatta GS, Mailliard RM, Gooding W, Palucka K, Banchereau J, Kalinski P.

Prostate. 2011 Feb 1;71(2):125-33. doi: 10.1002/pros.21228. Epub 2010 Aug 17.


Prostate cancer vaccines: current status and future potential.

Doehn C, Böhmer T, Kausch I, Sommerauer M, Jocham D.

BioDrugs. 2008;22(2):71-84. Review.


A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W.

Clin Cancer Res. 2006 Feb 15;12(4):1260-9.


Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG.

Cancer Res. 1999 Oct 15;59(20):5160-8.


Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.

Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG.

BJU Int. 2004 Aug;94(3):412-8.


A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellström M, Kiessling R, Masucci G, Wersäll P, Nilsson S, Pisa P.

Br J Cancer. 2004 Aug 16;91(4):688-94.


A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.

Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander RB, Jarvis MA.

J Immunother. 2012 Jun;35(5):390-9. doi: 10.1097/CJI.0b013e3182585d50.


A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression.

von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Peguillet I, Lantz O, Vellice A, Kohan A, Chacón M, Yee C, Wainstok R, Mordoh J.

J Transl Med. 2008 Jan 25;6:6. doi: 10.1186/1479-5876-6-6.


Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.

Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.

J Clin Immunol. 2007 Jan;27(1):117-30. Epub 2006 Dec 16.


Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM.

J Clin Oncol. 2004 Jun 1;22(11):2122-32.


Supplemental Content

Support Center